基于多源信息构建药品不良反应基准数据库

doi:10.19803/j.1672-8629.20240911

中国药物警戒 ›› 2025, Vol. 22 ›› Issue (1): 10-15.
DOI: 10.19803/j.1672-8629.20240911

• 药源性血小板减少研究专栏 • 上一篇下一篇

基于多源信息构建药品不良反应基准数据库

聂晓璐^1,2,3, 孙凤^2,3, 阎爱侠⁴, 彭晓霞^1,3#, 詹思延^2,*

¹国家儿童医学中心,首都医科大学附属北京儿童医院临床流行病与循证医学中心, 100045;
²北京大学公共卫生学院流行病与卫生统计学系,北京 100091;
³海南省真实世界数据研究院,海南琼海 571437;
⁴北京化工大学生命科学与技术学院,北京 100029

收稿日期:2024-11-25 出版日期:2025-01-15 发布日期:2025-01-22
通讯作者: ^*詹思延,教授·博导,药物流行病学与循证医学。E-mail: siyan-zhan@bjmu.edu.cn^#为共同通信作者。
作者简介:聂晓璐,女,副研究员,药物流行病学与循证医学。
基金资助:
国家自然科学基金资助项目（82204149）; 北京市医院管理中心“青苗”计划专项经费资助（QML20231204）; 北京儿童医院科研苗圃计划（3-1-014-01-04）; 海南博鳌乐城国际医疗旅游先行区真实世界研究专项计划项目（HNLC 2022RWS015）

Methodology for Constructing Benchmark Database of Adverse Drug Reactions Based on Multi-Source Information

NIE Xiaolu^1,2,3, SUN Feng^2,3, YAN Aixia⁴, PENG Xiaoxia^1,3#, ZHAN Siyan^2,*

¹Center for Clinical Epidemiology & Evidence-based Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China;
²Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100091, China;
³Hainan Institute of Real World Data, Qionghai Hainan 571437, China;
⁴College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China

Received:2024-11-25 Online:2025-01-15 Published:2025-01-22

摘要/Abstract

摘要： 目的总结现有主要药品不良反应（ADR）基准数据库构建信息来源,并以药源性血小板减少（DITP）为例综合多源数据构建ADR基准数据库,以期为今后开展计算模拟研究和指导临床安全用药提供参考。方法比较介绍现有各主要ADR基准数据库的信息来源优势与局限性;利用多源信息汇总构建DITP基准数据库,使用Kappa值评价各来源数据信息的一致性;利用药品解剖学、治疗学及化学分类法（ATC）编码分析DITP风险药物在解剖学分类中的分布情况与差异。结果利用美国食品药品监督管理局（FDA）推荐的多源信息来源方法构建了包含1 765种药物的DITP基准数据库（DITPst）。在DITPst数据库中,按照ATC编码解剖学分类划分,最常发生DITP的药物为抗肿瘤及免疫调节类药物,77.17%（196/254）可引起DITP。结论利用多源信息构建ADR基准数据库可为药物研发开展计算模拟研究及药品上市后安全与合理用药提供数据参考。

关键词: 药品不良反应, 药源性血小板减少, 基准数据库, 多源信息, 计算模拟研究, 抗肿瘤药物, 免疫调节类药物, 安全合理用药

Abstract: Objective To summarize the primary data sources used in constructing benchmark databases for adverse drug reactions (ADR) and to demonstrate a comprehensive, multi-source approach to building an ADR benchmark database using drug-induced thrombocytopenia (DITP) as an example so as to provide a reference for future computational modeling studies and to guide safer clinical drug use. Methods The advantages and limitations of the data sources used in existing ADR benchmark databases were compared and analyzed. A benchmark database for DITP was constructed by integrating data from multiple sources, and the consistency of these data sources was evaluated using the kappa statistic. The distribution and variability of DITP-risk drugs were analyzed based on the Anatomic Therapeutic Chemical (ATC) classification system. Results Using the FDA-recommended multi-source integration approach, a DITP benchmark database (DITPst) comprising 1 765 drugs was constructed. Analysis of the anatomical classification of drugs within the DITPst database revealed that antineoplastic and immunomodulating agents were the most frequently associated with DITP, with 77.17% (196/254) of these drugs identified as causing these ADR. Conclusion Constructing ADR benchmark databases using multi-source information provides a valuable data reference for computational modeling in drug development as well as for ensuring post-marketing drug safety and promoting rational drug use.

Key words: Adverse Drug Reaction, Drug-Induced Thrombocytopenia, Benchmark Database, Multi-Source Data, Computational Simulation Research, Antineoplastic Drug, Immunomodulating Drug, Safe and Rational Drug Use

中图分类号:

R994.1
R978

聂晓璐, 孙凤, 阎爱侠, 彭晓霞, 詹思延. 基于多源信息构建药品不良反应基准数据库[J]. 中国药物警戒, 2025, 22(1): 10-15.

NIE Xiaolu, SUN Feng, YAN Aixia, PENG Xiaoxia, ZHAN Siyan. Methodology for Constructing Benchmark Database of Adverse Drug Reactions Based on Multi-Source Information[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 10-15.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240911

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I1/10

参考文献

[1] KIRALY P, KISS R, KOVACS D, et al.The Relevance of Goodness-of-Fit, Robustness and Prediction Validation Categories of OECD-QSAR Principles with Respect to Sample Size and Model Type[J]. Molecular Informatics, 2022,41(11): e2200072.
[2] BELFIELD SJ, CRONIN MT, ENOCH SJ, et al.Guidance for Good Practice in the Application of Machine Learning in Development of Toxicological Quantitative Structure-Activity Relationships (QSARs)[J]. Plos One, 2023,18(5): e0282924.
[3] YAO KY, ZHANG SQ, JIN R, et al.Comparative Study on Data Set of Drug - Induced Liver Injury[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(5): 568-573.
[4] GREENE N, FISK L, NAVEN RT, et al.Developing Structure-Activity Relationships for the Prediction of Hepatotoxicity[J]. Chem Res Toxicol, 2010, 23(7): 1215-1222.
[5] NUSRAT S, BOROGOVAC A, GEORGE JN, et al.Drug (Vaccine)-Induced Thrombocytopenia 2021: Diversity of Pathogenesis and Clinical Features[J]. Am J Hematol, 2022, 97(4): E162-E165.
[6] GEORGE JN.Drug-Induced Thrombocytopenia[EB/OL]. [2023-06-30].https://ouhsc.edu/platelets/ditp.html.
[7] MCBURNEY RN, HINES WM, VON TUNGELN LS, et al.The Liver Toxicity Biomarker Study: Phase I Design and Preliminary Results[J]. Toxicol Pathol, 2009, 37(1): 52-64.
[8] CHEN M, SUZUKI A, THAKKAR S, et al.DILIrank: the Largest Reference Drug List Ranked by the Risk for Developing Drug-Induced Liver Injury in Humans[J]. Drug Discov Today, 2016, 21(4): 648-653.
[9] KUHN M, LETUNIC I, JENSEN LJ, et al.The SIDER Database of Drugs and Side Effects[J]. Nucleic Acids Res, 2016, 44(D1): D1075-D1079.
[10] KUHN M, CAMPILLOS M, LETUNIC I, et al.A Side Effect Resource to Capture Phenotypic Effects of Drugs[J]. Mol Syst Biol, 2010, 6: 343.
[11] LAB T.OnSIDES v2.0.0 Released[EB/OL]. [2023-06-30]. https://tatonettilab.org/onsides-v2-0-0-released/.
[12] O'BRIEN PJ, IRWIN W, DIAZ D, et al. High Concordance of Drug-Induced Human Hepatotoxicity with in Vitro Cytotoxicity Measured in a Novel Cell-Based Model Using High Content Screening[J]. Arch Toxicol 2006, 80(9): 580-604.
[13] XU JJ, HENSTOCK PV, DUNN MC, et al.Cellular Imaging Predictions of Clinical Drug-Induced Liver Injury[J]. Toxicol Sci, 2008, 105(1): 97-105.
[14] EKINS S, WILLIAMS AJ, XU JJ, et al.A Predictive Ligand-Based Bayesian Model for Human Drug-Induced Liver Injury[J]. Drug Metab Dispos, 2010, 38(12): 2302-2308.
[15] LOW Y, UEHARA T, MINOWA Y, et al.Predicting Drug-Induced Hepatotoxicity Using QSAR and Toxicogenomics Approaches[J]. Chem Res Toxicol, 2011, 24(8): 1251-1262.
[16] NIE XL, MA JY, SUN F, et al.Pathogenesis and Diagnosis of Drug-Indeced Thrombocytopenia[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(7): 829-835.
[17] RODGERS AD, ZHU H, FOURCHES D, et al.Modeling Liver-Related Adverse Effects of Drugs Using Knearest Neighbor Quantitative Structure-Activity Relationship Method[J]. Chem Res Toxicol, 2010, 23(4): 724-732.
[18] TATONETTI NP, YE PP, DANESHJOU R, et al. Data-Driven Prediction of Drug Effects and Interactions[J]. Sci Transl Med, 2012, 4(125): 125ra31.
[19] THAKKAR S, LI T, LIU Z, et al.Drug-Induced Liver Injury Severity and Toxicity (DILIst): Binary Classification of 1279 Drugs by Human Hepatotoxicity[J]. Drug Discov Today, 2020, 25(1): 201-208.
[20] HOOFNAGLE JH, SERRANO J, KNOBEN JE, et al.LiverTox: a Website on Drug-Induced Liver Injury[J]. Hepatology, 2013, 57(3): 873-874.
[21] LYU Q, CHEN G, HE H, et al.TCMBank-the Largest TCM Database Provides Deep Learning-Based Chinese-Western Medicine Exclusion Prediction[J]. Signal Transduct Target Ther, 2023, 8(1): 127.
[22] LYU Q, CHEN G, HE H, et al.TCMBank: Bridges between the Largest Herbal Medicines, Chemical Ingredients, Target Proteins, and Associated Diseases with Intelligence Text Mining[J]. Chem Sci, 2023, 14(39): 10684-10701.
[23] MARINI I, UZUN G, JAMAL K, et al.Treatment of Drug-Induced Immune Thrombocytopenias[J]. Haematologica, 2022, 107(6): 1264-1277.
[24] RODEGHIERO F.Introduction to a Review Series on the Treatment of Thrombocytopenic Disorders: Something Old, Something New[J]. Haematologica, 2022, 107(6): 1239-1242.
[25] LI DL.Drug-Induced Thrombocytopenia: Mechanism, Clinical Presentation, Treatment, and Prevention[J]. Guide of China Medicine(中国医药指南), 2020, 18(1): 76-77.
[26] National Medical Products Administration Center for Drug Evaluation. Pharmaceutical Products List Database for Publication(中国上市药品目录集数据库)[EB/OL].[2023-06-30]. https://www.cde.org.cn/hymlj/index.
[27] Side Effects. SIDER 4.1[DB/OL]. [2023-06-30]. http://sideeffects.embl.de.
[28] TLAB. OnSIDES v2.0.0[DB/OL]. [2023-06-30]. https://tatonettilab.org/onsides-v2-0-0-released/.
[29] YAO ZH.Search[DB/OL].[2023-06-30].https://db.yaozh.com/instruc.

基于多源信息构建药品不良反应基准数据库

Methodology for Constructing Benchmark Database of Adverse Drug Reactions Based on Multi-Source Information

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	聂晓璐, 赵厚宇, 霍东辉, 阎爱侠, 孙凤, 彭晓霞, 倪鑫, 詹思延. 基于真实世界数据与定量构效关系的儿童药源性免疫性血小板减少症研究[J]. 中国药物警戒, 2025, 22(1): 16-22.
[2]	邵波, 钟露苗, 成雨竹, 邓华, 朱兰. 银黄口服制剂安全性风险分析及思考[J]. 中国药物警戒, 2025, 22(1): 84-87.
[3]	赵秋月, 卫红涛, 李丹丹, 闫安, 邸宣. 阿加曲班注射液治疗急性缺血性脑卒中致消化道出血的不良反应分析[J]. 中国药物警戒, 2025, 22(1): 88-92.
[4]	戴彪, 曹银, 孙艳红, 张元元, 夏清荣. 808例抗精神病药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(1): 99-103.
[5]	程伟能, 潘秋娜, 杨静, 冯强, 汤晓萌, 梁悦. 763例药疹病例分析[J]. 中国药物警戒, 2025, 22(1): 104-108.
[6]	张维, 徐东杰, 金宇, 邹颖, 张婷, 周建成. 甲磺酸伏美替尼片致心力衰竭1例分析[J]. 中国药物警戒, 2025, 22(1): 113-115.
[7]	孟康康, 夏玉坤. 昂丹司琼制剂安全性风险分析[J]. 中国药物警戒, 2024, 21(9): 1034-1038.
[8]	吴凡, 付林杰, 祝赫, 徐梦艳. 基于美国FAERS和日本JADER数据库的内皮素受体拮抗剂不良事件信号分析[J]. 中国药物警戒, 2024, 21(9): 1056-1063.
[9]	卢靖, 喻珊珊, 童菲, 林卓慧, 宋路瑶. 达格列净片致严重便秘1例分析[J]. 中国药物警戒, 2024, 21(9): 1071-1074.
[10]	刘婷, 曹忠强, 何文佳, 袁秀丽, 陈泽彬, 李学娟. 培门冬酶注射液致急性重症胰腺炎1例分析[J]. 中国药物警戒, 2024, 21(9): 1075-1077.
[11]	魏芬芳, 吴文宇, 李丽敏, 唐碧雨, 吴建茹. 国外药品获益-风险评价方法概述与启示[J]. 中国药物警戒, 2024, 21(8): 900-905.
[12]	王玉玺, 张宗林, 王颖丽, 陈亚飞, 李俊生, 霍艳飞, 谢彦军, 刘文启. 560例脉络舒通丸不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 921-924.
[13]	赵俊, 董丽, 王洋, 梁瑜, 杨雪, 李恩泽. 艾司洛尔不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 925-930.
[14]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[15]	晁滢, 张学梅, 张成健, 王贝. 注射用头孢曲松钠致儿童输尿管结石及胆囊结石1例分析[J]. 中国药物警戒, 2024, 21(8): 943-945.